Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amplify Transformational Data Sharing ETF (BLOK) vs Enveric Biosciences Inc (ENVB) Price & Performance

Amplify Transformational Data Sharing ETFTrade
Enveric Biosciences IncTrade

Price performance (Past 24H)

Key statistics

Amplify Transformational Data Sharing ETF vs Enveric Biosciences Inc — how do they compare? Amplify Transformational Data Sharing ETF trades at $61.14, while Enveric Biosciences Inc trades at $1.28 (market cap $5.32M). The key difference: Amplify Transformational Data Sharing ETF is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.

BLOKENVB
52-Week High
$74.10$17.40
52-Week Low
$47.36$1.28
Market Cap
$5.32M
Sector
Health
Enterprise Value
$408.82K

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amplify Transformational Data Sharing ETF

BLOK trades at $60.81, down 2.95% today amid bearish technical signals. The stock faces selling pressure with moving averages indicating a downtrend, though oscillators remain neutral. Recent news highlights the fund's diversified blockchain economy exposure, including bitcoin miners and enterprise adopters. The company announced a $0.08 dividend scheduled for June 2026, providing income potential for shareholders.

Outlook remains cautious with technical indicators signaling bearish momentum. The fund's increased bitcoin exposure to approximately 40% introduces volatility risks, though diversification across AI infrastructure and payment processors offers some stability. Investment opportunity exists for long-term investors seeking blockchain economy exposure, but near-term performance depends heavily on crypto market direction and AI infrastructure growth.

Enveric Biosciences Inc

ENVB trades at $1.33, down 1.48% on the day, with a bearish technical signal from moving averages despite neutral oscillators. The company shows significant financial challenges with negative ROE of -257.95% and ROA of -218.01%, though it has consistently beaten earnings expectations in recent quarters. Recent news highlights active participation in investor conferences and progress with EB-003 drug candidate development.

While analyst consensus is 75% buy-rated, the stock faces substantial fundamental risks from negative profitability and cash burn. Investment opportunity exists if clinical developments succeed, but shareholders should weigh high operational losses against potential biotech breakthroughs in the neuroplastogenic therapeutics space.

Returns comparison

Trailing returns across standard periods

About Amplify Transformational Data Sharing ETF

The fund is an actively managed ETF that seeks to provide total return by investing at least 80% of its net assets in the equity securities of companies actively involved in the development and utilization of "transformational data sharing technologies". It may invest in non-US equity securities, including depositary receipts.

Read more on BLOK

About Enveric Biosciences Inc

Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.

Read more on ENVB